Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, explains why composite cognitive tests are valuable as outcome measures in degenerative disease studies. The goal of composite tests is to track the most progressive aspects of disease, to allow for a clearer result in the difference a treatment makes over time. By accounting for the progressive aspects, such as cognition, rather than episodic symptoms, the true disease-modifying value of a therapy on the core disease features can be realized. The composite tests advocated currently advocated for by Dr Hendrix include The Alzheimer’s Disease (AD) Composite Score (ADCOMS). This was used in the Phase II Clarity AD (NCT03887455) trial of lecanemab which efficiently measured progression of AD. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
